Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06050707
PHASE2

MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach

Sponsor: University Health Network, Toronto

View on ClinicalTrials.gov

Summary

The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2023-09-29

Completion Date

2028-09-01

Last Updated

2026-03-06

Healthy Volunteers

No

Interventions

RADIATION

Radiotherapy - Low risk group

20 fractions completed in 4 weeks

RADIATION

Radiotherapy - Standard risk group

25 fractions completed in 5 weeks

RADIATION

Radiotherapy - Intermediate risk group

30 fractions completed in 6 weeks

RADIATION

Radiotherapy - High risk group

35 fractions completed in 7 weeks

Locations (4)

Allegheny Health Network

Pittsburgh, Pennsylvania, United States

Medical College of Wisconsin Cancer Center

Milwaukee, Wisconsin, United States

Austin Health

Heidelberg, Victoria, Australia

Princess Margaret Cancer Centre

Toronto, Ontario, Canada